Question ID:
Legal Act:
Regulation (EU) No 575/2013 (CRR)
Market risk
COM Delegated or Implementing Acts/RTS/ITS/GLs/Recommendations:
Not applicable
Disclose name of institution / entity:
Type of submitter:
Investment firm
Subject Matter:
Treatment of contracts for difference under Article 327(1) or Regulation (EU) No 575/2013 (CRR)

Shall financial contracts for difference be treated as exposure in an underlying instrument?

Background on the question:

Treatment of financial contracts for difference (MiFID, Annex I, Section C, Point 9) is not described in Article 327 of CRR, although treatment of the other derivative categories is described. As they are different MiFID category than futures, options, warrants etc., it is not clear how they shall be treated.

Date of submission:
Published as Final Q&A:
Final Answer:

As per point 3 of Annex II to Regulation (EU) No 575/2013 (CRR), instruments specified in points 4 to 7, 9 and 10 of Section C of Annex I to Directive (EU) 2004/39/EC (MiFID) are a type of derivative. Point 9 in Section C of Annex 1 to MiFID is financial contracts for differences (CFDs). Hence, as per the CRR, financial CFDs are a type of derivative and should be treated as such for regulatory purposes.

A CFD can be considered as a derivative which synthetically replicates the performance of the underlying which means that the market risk is identical with a position in the underlying itself. Therefore CFDs should be treated as exposure to the amount of the underlying instrument to which they refer.

Final Q&A
Answer prepared by:
Answer prepared by the EBA.
Note to Q&A:

Update 26.03.2021: This Q&A has been reviewed in the light of the changes introduced to Regulation (EU) No 575/2013 (CRR) and continues to be relevant.